阿斯利康GLP-1口服药在糖尿病与肥胖症试验中通过早期考验

投资观察06-09

根据周一在美国糖尿病协会年度会议上公布的二期试验结果，阿斯利康的实验性GLP-1口服药在为期36周的治疗中，使肥胖患者的体重平均降低了近12%。同时，该药物将糖尿病患者的糖化血红蛋白水平——一项衡量血糖的关键指标——平均降低了1.9个百分点。

此项研究成果同步发表于《柳叶刀》杂志。这是这家英国制药巨头更广泛战略的一部分，其目标直指糖尿病、心脏病、肾衰竭及肝病，而非仅仅是美容减重。该公司押注于，随着减肥药物报销政策收紧，针对特定疾病的治疗将能继续获得保险支付方的支持。

阿斯利康首席执行官苏博科在一次采访中表示：“支付方，也就是最终买单的雇主们，开始思考，‘我希望人们健康，但未必愿意为那些只想在今年夏天去海滩前更好看的人付费。’我们想要向支付方证明，我们的药物能帮助各类患者。”

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1163381786?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-09 06:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163381786","market":"hk","top_or_hot":-1,"title":"阿斯利康GLP-1口服药在糖尿病与肥胖症试验中通过早期考验","media":"投资观察","content":"<p>根据周一在美国糖尿病协会年度会议上公布的二期试验结果，阿斯利康的实验性GLP-1口服药在为期36周的治疗中，使肥胖患者的体重平均降低了近12%。同时，该药物将糖尿病患者的糖化血红蛋白水平——一项衡量血糖的关键指标——平均降低了1.9个百分点。</p>\n<p>此项研究成果同步发表于《柳叶刀》杂志。这是这家英国制药巨头更广泛战略的一部分，其目标直指糖尿病、心脏病、肾衰竭及肝病，而非仅仅是美容减重。该公司押注于，随着减肥药物报销政策收紧，针对特定疾病的治疗将能继续获得保险支付方的支持。</p>\n<p>阿斯利康首席执行官苏博科在一次采访中表示：“支付方，也就是最终买单的雇主们，开始思考，‘我希望人们健康，但未必愿意为那些只想在今年夏天去海滩前更好看的人付费。’我们想要向支付方证明，我们的药物能帮助各类患者。”</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>阿斯利康GLP-1口服药在糖尿病与肥胖症试验中通过早期考验</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n阿斯利康GLP-1口服药在糖尿病与肥胖症试验中通过早期考验\n</h2>\n\n<h4 class=\"meta\">\n\n2026-06-09 06:27 北京时间&nbsp;&nbsp;&nbsp;<strong>投资观察</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>根据周一在美国糖尿病协会年度会议上公布的二期试验结果，阿斯利康的实验性GLP-1口服药在为期36周的治疗中，使肥胖患者的体重平均降低了近12%。同时，该药物将糖尿病患者的糖化血红蛋白水平——一项衡量血糖的关键指标——平均降低了1.9个百分点。\n此项研究成果同步发表于《柳叶刀》杂志。这是这家英国制药巨头更广泛战略的一部分，其目标直指糖尿病、心脏病、肾衰竭及肝病，而非仅仅是美容减重。该公司押注于，随着...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2456880835.USD","symbol_name":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","start_time":0,"source_url":"","article_id":"1163381786","we_media_id":"1076224072","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163381786","pubTimestamp":1780957629,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"投资观察","introduction":"关注海外资本市场一手动态","home_visible":1,"id":"1076224072","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"根据周一在美国糖尿病协会年度会议上公布的二期试验结果，阿斯利康的实验性GLP-1口服药在为期36周的治疗中，使肥胖患者的体重平均降低了近12%。同时，该药物将糖尿病患者的糖化血红蛋白水平——一项衡量血糖的关键指标——平均降低了1.9个百分点。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4568":"美国抗疫概念","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","BK4588":"碎股","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","BK4007":"制药","LU0058720904.USD":"联博国际健康护理基金A","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","BK4144":"石油与天然气的储存和运输","GLP":"Global Partners Lp","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","AZN":"阿斯利康","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","AZNH":"ASTRAZENECA PLC ADRhedged","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","BK4590":"PTP","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","BK4585":"ETF&股票定投概念","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H"},"translate_title":"AstraZeneca GLP-1 oral drug passes early test in diabetes and obesity trial","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZNH":1,"GLP":1,"AZN":1},"content_text":"根据周一在美国糖尿病协会年度会议上公布的二期试验结果，阿斯利康的实验性GLP-1口服药在为期36周的治疗中，使肥胖患者的体重平均降低了近12%。同时，该药物将糖尿病患者的糖化血红蛋白水平——一项衡量血糖的关键指标——平均降低了1.9个百分点。\n此项研究成果同步发表于《柳叶刀》杂志。这是这家英国制药巨头更广泛战略的一部分，其目标直指糖尿病、心脏病、肾衰竭及肝病，而非仅仅是美容减重。该公司押注于，随着减肥药物报销政策收紧，针对特定疾病的治疗将能继续获得保险支付方的支持。\n阿斯利康首席执行官苏博科在一次采访中表示：“支付方，也就是最终买单的雇主们，开始思考，‘我希望人们健康，但未必愿意为那些只想在今年夏天去海滩前更好看的人付费。’我们想要向支付方证明，我们的药物能帮助各类患者。”","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1163381786","isCrawlerRequest":true}